APPROVED QUOTES  

Attribution: Kirstin Thomas, Co-founder, KindredMind  

Quote 1 — "KindredMind was built to support both the person living with dementia and the caregiver. It offers familiar reassurance in the voice a loved one knows and trusts, helping reduce anxiety and repetitive calls without replacing the caregiver. The goal is simple: help families stay connected while giving caregivers a little more room to manage work, family, and daily life."  

Quote 2 — "KindredMind does not replace the caregiver. It steps in when they cannot answer, in the voice their loved one trusts."  

Quote 3 — "My mom would call me sometimes ten times before lunch. The existing tools told me to block her calls. None of them addressed why she was calling. She was scared, and she wanted me. I needed something that could be me when I could not take her call."  

Quote 4 — "KindredMind was built from both research and real life — from learning what actually helps when someone you love is scared and looking for you."   

Attribution: Patrick Armstrong, Co-founder, KindredMind  

Quote 1 — Technical / engineering: "We did not build this to replace humans. We built it because Kirstin needed to be in two places at once and could not. Every system in KindredMind exists to support the caregiver and answer the loved one's anxiety. Neither one gets replaced. Both get held."
   

APPROVED STATISTICS  

For use in articles and press materials:  

"Sometimes ten times before lunch" — approved phrasing for Sharon's call frequency to Kirstin 

"Approximately 90% call resolution rate" — only approved KindredMind success metric 

"20 minutes" — guided setup interview that captures the caregiver's voice and builds the loved one's knowledge base 

"11 languages" — number of languages KindredMind supports 

"24/7" — availability of the AI voice companion 

"Three layers" — emergency failsafe protections that route urgent needs to a human caregiver 

"5%" — percentage of every subscription donated to Alzheimer Society of Canada, Alzheimer's Association in the United States or Alzheimer's Foundation of America 

"PubMed 38646703" — 2024 randomized controlled trial supporting simulated presence therapy  


CLINICAL CITATION  

For clinical references: Duan Q, Liu X, Zhang A. Effectiveness of simulated presence therapy for dementia patients. International Journal of Neuroscience. 2025 September; 135(9):1070-1080. PMID: 38646703.